DK1893747T3 - Isolerede celler og populationer, der omfatter sådanne celler, til behandling af cns-sygdomme - Google Patents
Isolerede celler og populationer, der omfatter sådanne celler, til behandling af cns-sygdomme Download PDFInfo
- Publication number
- DK1893747T3 DK1893747T3 DK06766101.7T DK06766101T DK1893747T3 DK 1893747 T3 DK1893747 T3 DK 1893747T3 DK 06766101 T DK06766101 T DK 06766101T DK 1893747 T3 DK1893747 T3 DK 1893747T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- cell
- astrocyte
- phenotype
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
Claims (7)
- ISOLEREDE CELLER OG POPULATIONER, DER OMFATTER SÅDANNE CELLER, TIL BEHANDLING AF CNS-SYGDOMME1. Fremgangsmåde til dannelse af astrocytlignende celler, hvilken fremgangsmåde omfatter: (a) inkubering af mesenkymale stamceller i et medium, som omfatter human epidermal vækstfaktor (hEGF) og human basisk fibroblastvækstfaktor (hbFGF), for at danne celler, som er prædisponeret for at udvikle sig til astrocytlignende celler; og (b) inkubering af de prædisponerede celler i et differentieringsmedium, som omfatter trombocytvækstfaktor (PDGF) og human neuregulin 1-β1, idet der derved dannes astrocytlignende celler.
- 2. Fremgangsmåde ifølge krav 1, hvor inkuberingen i trin (b) har en varighed på ca. 48 timer.
- 3. Fremgangsmåde ifølge krav 1, hvor koncentrationen af PDGF er ca. 5 ng/ml.
- 4. Fremgangsmåde ifølge krav 1, hvor koncentrationen af human neuregulin 1-β1 er ca. 50 ng/ml.
- 5. Fremgangsmåde ifølge krav 1, hvor differentieringsmediet endvidere omfatter L-glutamin, dibutyryl-cyklisk AMP og isobutylmethylxanthin IBMX.
- 6. Fremgangsmåde ifølge krav 1, hvor koncentrationen af hEGF er ca. 20 ng/ml.
- 7. Fremgangsmåde ifølge krav 1, hvor koncentrationen af hbFGF er ca. 20 ng/ml.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69087905P | 2005-06-16 | 2005-06-16 | |
PCT/IL2006/000699 WO2006134602A2 (en) | 2005-06-16 | 2006-06-18 | Isolated cells and populations comprising same for the treatment of cns diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1893747T3 true DK1893747T3 (da) | 2014-12-01 |
Family
ID=36992707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06766101.7T DK1893747T3 (da) | 2005-06-16 | 2006-06-18 | Isolerede celler og populationer, der omfatter sådanne celler, til behandling af cns-sygdomme |
Country Status (8)
Country | Link |
---|---|
US (3) | US8647874B2 (da) |
EP (2) | EP1893747B1 (da) |
JP (1) | JP2008546385A (da) |
CN (1) | CN101243178A (da) |
DK (1) | DK1893747T3 (da) |
ES (1) | ES2524996T3 (da) |
WO (1) | WO2006134602A2 (da) |
ZA (1) | ZA200711117B (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050265983A1 (en) * | 2002-11-17 | 2005-12-01 | Eldad Melamed | Methods, nucleic acid constructs and cells for treating neurodegenerative disorders |
ES2524996T3 (es) | 2005-06-16 | 2014-12-16 | Ramot At Tel Aviv University Ltd. | Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC |
WO2007066338A1 (en) * | 2005-12-08 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases |
DK2086332T3 (da) * | 2006-11-03 | 2018-04-16 | Multiple Sclerosis Res Center Of New York | Mesenchymale stamceller der er afledt af benmarv som en kilde til neurale progenitorer |
DE102007044487A1 (de) * | 2007-09-18 | 2009-04-02 | Universität Leipzig | Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe |
DK2620493T3 (da) | 2008-05-28 | 2019-07-01 | Univ Ramot | Mesenkymale stamceller til behandling af CNS-sygdomme |
CN102439136A (zh) | 2009-03-26 | 2012-05-02 | 加州大学校董 | 产生用于疾病修饰的抑制性rna的间充质干细胞 |
WO2011065208A1 (en) * | 2009-11-27 | 2011-06-03 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and method for manufacturing the same |
US9783781B2 (en) | 2010-08-16 | 2017-10-10 | Exostem Biotec Ltd. | Methods of generating oligodendrocytes and cell populations comprising same |
US10385314B2 (en) | 2010-08-16 | 2019-08-20 | Exostem Biotec Ltd. | Methods of generating oligodendrocytes and cell populations comprising same |
CN102021143B (zh) * | 2010-11-24 | 2012-07-25 | 浙江大学 | 一种提高间充质干细胞迁移能力的预处理方法 |
CN102327613A (zh) * | 2011-09-02 | 2012-01-25 | 浙江大学 | ErbB受体激动剂在制备治疗癫痫病的药物中的应用 |
WO2013076726A1 (en) | 2011-11-21 | 2013-05-30 | Ramot At Tel-Aviv University Ltd. | Stem cell-derived neural cells for cell therapy in neurological disorders |
WO2013124815A2 (en) | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof |
JP2015509366A (ja) | 2012-02-22 | 2015-03-30 | ブレインステム バイオテック リミテッド | 神経幹細胞および運動ニューロンの生成 |
JP6329911B2 (ja) * | 2012-02-22 | 2018-05-23 | ブレインステム バイオテック リミテッド | 星状膠細胞作製のためのミクロrna |
CN102716467A (zh) * | 2012-04-28 | 2012-10-10 | 中国人民解放军第三军医大学第一附属医院 | 肝细胞生长因子在制备治疗多发性硬化症的药物中的应用 |
ES2813407T3 (es) | 2012-08-06 | 2021-03-23 | Brainstorm Cell Therapeutics Ltd | Métodos para generar células madre mesenquimales que secretan factores neurotróficos |
US20140065110A1 (en) | 2012-08-31 | 2014-03-06 | The Regents Of The University Of California | Genetically modified msc and therapeutic methods |
EP3058063B1 (en) | 2013-10-14 | 2018-06-06 | Hadasit Medical Research Services and Development Ltd. | Method of obtaining terminally differentiated neuronal lineages |
JP6628253B2 (ja) * | 2014-02-11 | 2020-01-08 | ブレインストーム セル セラペウティクス リミテッド | 細胞の適性を判定する方法 |
US11827904B2 (en) | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
WO2017056092A1 (en) | 2015-09-30 | 2017-04-06 | Hadasit Medical Research Services And Development Ltd. | Use of full-length amelogenin for promoting nerve growth or regeneration |
KR102363146B1 (ko) | 2016-03-09 | 2022-02-14 | 아비타 인터내셔널 리미티드 | 간엽 마커와 뉴런 마커를 발현하는 줄기 세포, 이의 조성물 및 이의 제조 방법 |
EP3231434A1 (en) * | 2016-04-14 | 2017-10-18 | Fundacio Centre de Regulacio Genomica | Method of treatment of parkinsonism |
AU2017265937A1 (en) * | 2016-05-16 | 2018-11-22 | Exostem Biotec Ltd. | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases |
EP3842049A1 (en) * | 2016-07-18 | 2021-06-30 | Brainstorm Cell Therapeutics Ltd. | Methods for diagnosing amyotrophic lateral sclerosis (als) |
CN110133272A (zh) * | 2018-02-09 | 2019-08-16 | 北京大学 | 用于从生物体液中富集或检测星形胶质细胞来源的外泌体的方法 |
CN108359638B (zh) * | 2018-04-04 | 2020-02-14 | 浙江霍德生物工程有限公司 | 功能大脑皮层细胞的诱导分化方法 |
WO2023281502A1 (en) * | 2021-07-06 | 2023-01-12 | Brainstorm Cell Therapeutics Ltd. | Methods of generating mesenchyal stem cells which secrete neurotrophic factors in a bioreactor system |
WO2023095149A1 (en) | 2021-11-29 | 2023-06-01 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating spinal cord injury |
WO2024009246A1 (en) * | 2022-07-08 | 2024-01-11 | Friedrich Miescher Institute For Biomedical Research | Culture medium suitable for the differentiation and culture of intestinal organoids |
CN115813951B (zh) * | 2022-11-10 | 2023-07-21 | 北京昱龙盛世生物科技有限公司 | 转基因干细胞及其用于治疗失眠症或睡眠障碍的用途 |
CN116410921B (zh) * | 2023-02-09 | 2024-01-23 | 北京益华生物科技有限公司 | 一种人源脐带间充质干细胞诱导培养基、诱导方法及应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
US5780587A (en) * | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
JP3044689B2 (ja) | 1994-10-14 | 2000-05-22 | 日本ゼオン株式会社 | 感光性エラストマー組成物及び感光性ゴム版 |
US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
AU1979897A (en) | 1996-03-04 | 1997-09-22 | University Of Medicine And Dentistry Of New Jersey | Genetically engineered primary oligodendrocytes for transplantation-mediated gene delivery in the central nervous system |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
ES2246085T3 (es) | 1998-05-07 | 2006-02-01 | University Of South Florida | Celulas de medula osea como fuente de neuronas util para reparar la medula espinal y el cerebro. |
US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
ATE514772T1 (de) * | 1999-08-05 | 2011-07-15 | Abt Holding Co | Multipotente erwachsene stammzellen und verfahren zu deren isolierung |
US20040208858A1 (en) | 2000-04-12 | 2004-10-21 | Gihan Tennekoon | Therapeutic uses for mesenchymal stromal cells |
US6673606B1 (en) | 2000-04-12 | 2004-01-06 | The Children's Hospital Of Philadelphia | Therapeutic uses for mesenchymal stromal cells |
JP5943533B2 (ja) | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | 神経前駆細胞の集団 |
US6576464B2 (en) * | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
IL157332A0 (en) * | 2001-02-14 | 2004-02-19 | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof | |
KR100449141B1 (ko) * | 2001-04-19 | 2004-09-21 | (주)라이프코드 | 간엽 간세포를 신경세포로 분화시키는 방법 |
EP1478384A2 (en) | 2001-06-11 | 2004-11-24 | Ludwig Institute For Cancer Research | Method for increasing the survival of dopamine secreting cells |
JP3886346B2 (ja) | 2001-06-22 | 2007-02-28 | サンバイオ,インコーポレイティド | 骨髄間質細胞由来Schwann細胞を含む神経再生用医薬組成物 |
US9969980B2 (en) * | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
BR0306902A (pt) | 2002-01-14 | 2006-04-11 | Ford Henry Health System | materiais de células estromais de medula óssea para uso na formação de vasos sanguìneos e produção de fatores angiogênicos e tróficos |
US7682825B2 (en) | 2002-02-06 | 2010-03-23 | Sanbio, Inc. | Differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene |
US20050265983A1 (en) | 2002-11-17 | 2005-12-01 | Eldad Melamed | Methods, nucleic acid constructs and cells for treating neurodegenerative disorders |
IL152905A0 (en) | 2002-11-17 | 2003-06-24 | Univ Ramot | Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease |
US20070178591A1 (en) * | 2004-06-25 | 2007-08-02 | Renomedix Institute, Inc | Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient |
EP1658853A4 (en) * | 2003-06-27 | 2009-07-08 | Renomedix Inst Inc | MEDIUM FOR INTERNAL ADMINISTRATION FOR DISEASES OF NERVES IN THE HEAD WITH MESENCYCLES AS AN ACTIVE SUBSTANCE |
ES2524996T3 (es) | 2005-06-16 | 2014-12-16 | Ramot At Tel Aviv University Ltd. | Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC |
WO2007066338A1 (en) | 2005-12-08 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases |
DK2620493T3 (da) | 2008-05-28 | 2019-07-01 | Univ Ramot | Mesenkymale stamceller til behandling af CNS-sygdomme |
-
2006
- 2006-06-18 ES ES06766101.7T patent/ES2524996T3/es active Active
- 2006-06-18 EP EP06766101.7A patent/EP1893747B1/en active Active
- 2006-06-18 WO PCT/IL2006/000699 patent/WO2006134602A2/en active Application Filing
- 2006-06-18 JP JP2008516505A patent/JP2008546385A/ja active Pending
- 2006-06-18 EP EP11000994A patent/EP2465924A3/en not_active Withdrawn
- 2006-06-18 CN CNA2006800295872A patent/CN101243178A/zh active Pending
- 2006-06-18 DK DK06766101.7T patent/DK1893747T3/da active
-
2007
- 2007-03-27 US US11/727,583 patent/US8647874B2/en active Active
- 2007-12-20 ZA ZA200711117A patent/ZA200711117B/xx unknown
-
2014
- 2014-02-06 US US14/173,846 patent/US9879225B2/en active Active
-
2017
- 2017-11-22 US US15/820,521 patent/US10869899B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8647874B2 (en) | 2014-02-11 |
EP2465924A3 (en) | 2013-01-02 |
JP2008546385A (ja) | 2008-12-25 |
US10869899B2 (en) | 2020-12-22 |
WO2006134602A3 (en) | 2007-03-01 |
EP1893747A2 (en) | 2008-03-05 |
US9879225B2 (en) | 2018-01-30 |
US20140154222A1 (en) | 2014-06-05 |
WO2006134602A2 (en) | 2006-12-21 |
ES2524996T3 (es) | 2014-12-16 |
ZA200711117B (en) | 2008-10-29 |
EP2465924A2 (en) | 2012-06-20 |
EP1893747B1 (en) | 2014-09-03 |
CN101243178A (zh) | 2008-08-13 |
US20090010895A1 (en) | 2009-01-08 |
US20180112185A1 (en) | 2018-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1893747T3 (da) | Isolerede celler og populationer, der omfatter sådanne celler, til behandling af cns-sygdomme | |
US11185572B2 (en) | Mesenchymal stem cells for the treatment of CNS diseases | |
AU2002324645C1 (en) | Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof | |
AU2002324645A1 (en) | Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof | |
WO2007066338A1 (en) | Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases | |
WO2009023251A1 (en) | Methods and compositions for treating neural degeneration | |
US20090257987A1 (en) | Method of generating dopamine-secreting cells | |
Moses et al. | Fetal striatum-and ventral mesencephalon–derived expanded neurospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo | |
Chaturvedi et al. | Zuckerkandl's organ improves long-term survival and function of neural stem cell derived dopaminergic neurons in Parkinsonian rats | |
AU2007201401A1 (en) | Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases | |
WO2010030199A1 (en) | Stem cell culture | |
WO2007138577A2 (en) | Methods of generating a neural tissue using muscle-derived cells | |
Khoo | In Vitro and In Vivo neuronal differentiation capacity of human adult bone marrow-derived mesenchymal stem cells |